NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate
This article was originally published in The Pink Sheet Daily
Deal shows - once again - that all is not lost when Big Pharma hands back a product
You may also be interested in...
The tiny German biotech, vasopharm, aims to maximize the attractiveness of its NO-synthase inhibitor for potential partners, and to keep the flag flying for nitric oxide research.
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
France's NicOx, aiming to transform into a specialty ophthalmology company after several late-stage disappointments, announced plans to acquire VC-backed U.K startup Altacor.